Therapeutic Area: Oncology
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran et al.
New England Journal of Medicine
Papers
December 2016
Authors and Affiliates
Eric Tran, Ph.D., Paul F. Robbins, Ph.D., Yong‐Chen Lu, Ph.D., Todd D. Prickett, Ph.D., Jared J. Gartner, M.Sc., Li Jia, M.Sc., Anna Pasetto, Ph.D., Zhili Zheng, Ph.D., Satyajit Ray, Ph.D., Eric M. Groh, M.D., Isaac R. Kriley, M.D., and Steven A. Rosenberg, M.D., Ph.D.
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells
Boddupalli et al
Journal of Clinical Investigation
Papers
December 2016
Authors and Affiliates
Chandra Sekhar Boddupalli,1 No ar Bar,1 Krishna Kadaveru,2 Michael Krauthammer,3,4 Natopol Pornputtapong,4 Zifeng Mai,2 Stephan Ariyan,5 Deepak Narayan,5 Harriet Kluger,1,6 Yanhong Deng,7 Rakesh Verma,1 Rituparna Das,1 Antonella Bacchiocchi,8 Ruth Halaban,8 Mario Sznol,1,6 Madhav V. Dhodapkar,1,6,9 and Kavita M. Dhodapkar2,6
1Department of Medicine, 2Department of Pediatrics, 3Program for Computational Biology and Bioinformatics, 4Department of Pathology, 5Department of Surgery, 6Yale Cancer Center, 7Yale Center for Analytic Sciences, 8Department of Dermatology, 9Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity
Crittenden et al.
Papers
Scientific Reports
December 2016
Authors and Affiliates
Marka R. Crittenden1,2, Lauren Zebertavage3, Gwen Kramer1, Shelly Bambina1, David Friedman1, Victoria Troesch1, Tiffany Blair3, Jason R. Baird1, Alejandro Alice1 & Michael J. Gough1
1Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR, 97213, USA. 2The Oregon Clinic, Portland, OR, 97213, USA. 3Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR, 97239, USA.
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson et al.
New England Journal of Medicine
Papers
November 2016
Authors and Affiliates
Douglas B. Johnson, M.D.,1 Justin M. Balko, PharmD, Ph.D.,1,2,4 Margaret L. Compton, M.D.,5 Spyridon Chalkias, M.D.,10,11 Joshua Gorham, B.A.,14 Yaomin Xu, Ph.D.,6,8,9 Mellissa Hicks, Ph.D.,1 Igor Puzanov, M.D.,1 Matthew R. Alexander, M.D., Ph.D.,1 Tyler L. Bloomer, M.D.,1 Jason Becker, M.D.,1 David A. Slosky, M.D.,1,3 Elizabeth J. Phillips, M.D.,1 Mark A. Pilkinton, M.D., Ph.D.,1 Laura Craig-Owens, M.D.,5 Nina Kola, M.D.,16 Gregory Plautz, M.D.,16 Daniel S. Reshef, M.D.,16 Jonathan S. Deutsch, M.D.,16 Raquel P. Deering, Ph.D.,17 Benjamin A. Olenchock, M.D., Ph.D.,12 Andrew H. Lichtman, M.D.,13 Dan M. Roden, M.D.,1,7,8 Christine E. Seidman, M.D.,12,14,15 Igor J. Koralnik, M.D.,11 Jonathan G. Seidman, Ph.D.,12,14 Robert D. Hoffman, M.D., Ph.D.,5 Janis M. Taube, M.D.,18,19 Luis A. Diaz, Jr., M.D.,20 Robert A. Anders, M.D.,18 Jeffrey A. Sosman, M.D.,1 and Javid J. Moslehi, M.D.1,2,3
1Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
2Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN
3Department of Cardio-Oncology Program, Vanderbilt University Medical Center, Nashville, TN
4Department of Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, TN
5Department of Pathology Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN
6Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN
7Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN
8Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN
9Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN
10Department of Medicine, Beth Israel Deaconess Medicine Center, Boston, MA
11Division of Neuro-Immunology, Beth Israel Deaconess Medicine Center, Boston, MA
12Department of Medicine, Brigham and Women’s Hospital, Boston, MA
13Department of Pathology, Brigham and Women’s Hospital, Boston, MA
14Department of Genetics, Howard Hughes Medical Institute, Boston, MA
15Harvard Medical School, Howard Hughes Medical Institute, Boston, MA
16Bristol Myers Squibb, New York, NY
17Neon Therapeutics, Cambridge, MA
18Department of Pathology, Johns Hopkins University, Baltimore, MD
19Department of Dermatology, Johns Hopkins University, Baltimore, MD
20Department of Oncology, Johns Hopkins University, Baltimore, MD
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
Authors and Affiliates
Sumit K. Subudhia,1, Ana Aparicioa,1, Jianjun Gaoa, Amado J. Zuritaa, John C. Araujoa, Christopher J. Logothetisa, Salahaldin A. Tahira, Brinda R. Korivib, Rebecca S. Slackc, Luis Venced, Ryan O. Emersone, Erik Yuskoe, Marissa Vignalie,
Harlan S. Robinse,f, Jingjing Sung, James P. Allisond,g,2, and Padmanee Sharmaa,d,g,2
aDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030; bDepartment of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030; cDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030; dImmunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX 77030; eAdaptive Biotechnologies, Seattle, WA 98102; fFred Hutchinson Cancer Research Center, Seattle, WA 98102; and gDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030
Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide
Weir et al
Journal for ImmunoTherapy of Cancer
Papers
October 2016
Authors and Affiliates
Genevieve M. Weir1*, Olga Hrytsenko1, Tara Quinton1, Neil L. Berinstein2,3, Marianne M. Stanford1,4 and Marc Mansour1
1 Immunovaccine Inc., 1344 Summer St., Halifax, NS B3H 0A8, Canada. 2 Sunnybrook Research Institute, 2075 Bayview Ave., Toronto, ON M4N 3M5, Canada. 3 University of Toronto, 27 King’s College Cir, Toronto, ON M5S 1A1, Canada. 4 Department of Microbiology & Immunology, Dalhousie University, 5850 College St., Room 7C, Halifax, NS B3H 4R2, Canada.
Deep Sequencing of T-Cell Receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy
Authors and Affiliates
David B. Page1,2, Jianda Yuan1, David Redmond3, Y Hanna Wen1, Jeremy C. Durack1, Ryan Emerson4, Stephen Solomon1, Zhiwan Dong1, Phillip Wong1, Christopher Comstock1, Adi Diab5, Janice Sung1, Majid Maybody1, Elizabeth Morris1, Edi Brogi1, Monica Morrow1, Virgilio Sacchini1, Olivier Elemento3, Harlan Robins6, Sujata Patil1, James P. Allison5, Jedd D. Wolchok1,3, Clifford Hudis1,3, Larry Norton1,3, and Heather McArthur1,3
1Medical Oncology, Providence Portland Medical Center / Robert W. Franz Cancer Research Center and Earl A. Chiles Research Institute; 2Memorial Sloan-Kettering Cancer Center; 3Weill Cornell Medical College 4Adaptive Biotechnologies; 5Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center; 6Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medical College; 7Human Biology Division, Fred Hutchinson Cancer Research Center; 8Immunology, University of Texas MD Anderson Cancer Center; 9Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center; 10Medicine, Breast Medicine Service, Memorial Sloan-Kettering Cancer Center
The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphoma
Authors and Affiliates
1,2Colm Keane, 1,2Clare Gould, 1Kimberley Jones, 3David Hamm, 5,6Dipti Talaulikar, 1Jonathan Ellis, 1Frank Vari, 2,7Simone Birch 1Erica Han, 2Peter Wood, 1Kim-Anh Le-Cao, 4Michael R. Green, 1Pauline Crooks, 5Sanjiv Jain, 1,2Josh Tobin, 1Raymond J. Steptoe, 1,2Maher K. Gandhi.
1University of Queensland Diamantina Institute, Translational Research Institute, University of Queensland, Australia;2Princess Alexandra Hospital, Brisbane, Queensland, Australia; 3Adaptive Biotechnologies, Seattle, WA, USA, 4Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Nebraska, USA. 5Canberra Hospital, Canberra, Australian Capital Territory; 6Australian National University Medical School, Australian Capital Territory; 7Pathology Queensland, Brisbane, Queensland, Australia.
Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease
Henriksen et al.
Journal of Hepatology
Papers
September 2016
Authors and Affiliates
Eva Kristine Klemsdal Henriksen1,2,3,4, Kristin Kaasen Jørgensen1,5, Fatemeh Kaveh3,4,6, Kristian Holm1,2,3,4, David Hamm7, Johanna Olweus3,8,9, Espen Melum1,2,3,10, Brian K. Chung1,4,13, Tor J. Eide4,11, Knut E.A. Lundin10,12, Kirsten Muri Boberg1,3,4,10, Tom H. Karlsen1,2,3,4,10,Gideon M. Hirschfield13, Evaggelia Liaskou13,⇑
1Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammatory Medicine and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway; 2Research Institute of Internal Medicine, Division of Surgery, Inflammatory Medicine and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway; 3K.G. Jebsen Inflammation Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; 4Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; 5Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; 6Department of Medical Genetics, Oslo University Hospital Ullevål, Oslo, Norway; 7Adaptive Biotechnologies Corp., Seattle, WA, USA; 8Department of Cancer Immunology, Institute for Cancer Research,Oslo University Hospital Radiumhospitalet, Oslo, Norway; 9K.G. Jebsen Center for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; 10Section of Gastroenterology, Department of Transplantation Medicine, Division of Surgery, Inflammatory Medicine and Transplantation, Oslo University Hospital Rikshospitalet, Oslo, Norway; 11Department of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway; 12Centre for Immune Regulation, Faculty of Medicine, University of Oslo, Oslo, Norway; 13Centre for Liver Research and NIHR Birmingham Biomedical Research Unit, Institute of Biomedical Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK